Christopher Heery - Aug 26, 2024 Form 4 Insider Report for Arcellx, Inc. (ACLX)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Michelle Gilson, as Attorney-in-Fact
Stock symbol
ACLX
Transactions as of
Aug 26, 2024
Transactions value $
-$1,217,014
Form type
4
Date filed
8/28/2024, 04:54 PM
Previous filing
Aug 19, 2024
Next filing
Sep 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACLX Common Stock Options Exercise $325K +21.7K +233.71% $15.00 31K Aug 26, 2024 Direct
transaction ACLX Common Stock Sale -$454K -6.43K -20.77% $70.61 24.5K Aug 26, 2024 Direct F1, F2
transaction ACLX Common Stock Sale -$1.09M -15.3K -62.18% $71.34 9.28K Aug 26, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACLX Stock Option (right to buy) Options Exercise $0 -21.7K -12.08% $0.00 158K Aug 26, 2024 Common Stock 21.7K $15.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 22, 2023.
F2 Represents the weighted average share price of an aggregate total of 6,432 shares sold in the price range of $70.00 to $70.99 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 15,252 shares sold in the price range of $71.00 to $71.73 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022.